

August 7, 2026

One-offs led PAT decline; Strong pipeline & deal wins reinforce growth outlook...

About the stock: Firstsource Solutions (FSL) provides business process services to BFSI, communication, media, tech & healthcare. It has 200+ global clients, including several Fortune-500 & FTSE-100 companies.

Q1FY27 performance: Revenues came at US\$288 million, up 1.8% QoQ/11.2% YoY in US\$ terms (up 2.2% QoQ/12.3% YoY CC). EBIT margin expanded to 12.4%, up ~20 bps QoQ/~110 bps YoY. Reported PAT stood at ₹165.9 crore, down 19.2% QoQ/2% YoY impacted by ₹71.7 crore of exceptional items relating to i) ₹35.7 crore provision for estimated non-recoverable dues following the termination of a healthcare BPaaS client contract, (ii) ₹28.4 crore indemnification for a regulatory penalty payable to a healthcare segment client due to contractual non-fulfilment, and (iii) ₹7.6 crore fair value adjustment on contingent consideration related to an earlier acquisition

Investment Rationale:

- Record deal momentum and robust pipeline provide strong earnings visibility: The company continues to demonstrate healthy execution with its sixth consecutive quarter of 4 or more large deal wins, highest ACV intake in the last 4 quarters and a deal pipeline exceeding US\$1 billion. Despite the wind-down of a healthcare BPaaS engagement that was expected to contribute 1–1.5% to FY27 growth, **management reaffirmed its 10–13% CC (~9.5% organic) revenue growth guidance for FY27**, supported by add on work from the same client, strong deal pipeline, recent large deals ramp-up and continued new logo additions.. **We expect US\$ revenue to grow at CAGR of 10.2% over FY26-28E.**
- Margin expansion story remains intact: EBIT margin expansion, was driven by delivery optimization, AI-led productivity gains, right-shoring and disciplined execution. **Management has reiterated its FY27 EBIT margin guidance of 12.25–12.75% and with 14–15% EBIT margin target over the next two to three years** despite ongoing investments in AI capabilities, new growth engines and strategic partnerships. We believe improving operating leverage and increasing adoption of AI-led delivery models should continue to support steady margin expansion. **We have baked in EBIT margins of 12.4%/12.6% for FY27E/FY28E.**
- AI-led transformation and expanding wallet share support sustainable above-industry growth:** FSL continues to strengthen its positioning as an AI-first, outcome-based business transformation partner through its Intelligence That Operates strategy and Kairos platform. Strong traction in intelligent operations, healthcare revenue cycle management, financial crime, collections and customer experience, coupled with deeper relationships with hyperscalers and AI ecosystem partners, is expanding wallet share across existing clients. On the back of this the management expects to deliver top decile growth in the industry.

Rating and Target Price: We believe execution is likely going to be towards the mid to lower end of the guidance, which we had already built in earlier, in our numbers as well. Thus, we maintain **BUY rating, with a target price of ₹340; valuing it at 21x P/E on FY28E EPS.**

Key Financial Summary

₹ crore	FY24	FY25	FY26	5 year CAGR (FY21-26)	FY27E	FY28E	2 year CAGR (FY26-28E)
Net Sales	6,336	7,980	9,556	13.5%	11,195	12,288	13.4%
EBITDA	956	1,208	1,556	14.3%	1,883	2,101	16.2%
EBITDA Margins (%)	15.1	15.1	16.3		16.8	17.1	
Net Profit	515	594	674	13.3%	908	1,125	29.2%
EPS (₹)	7.3	8.5	9.6		12.9	16.0	
P/E	37.8	32.7	28.9		21.4	17.3	
RoNW (%)	13.9	14.5	15.4		18.6	20.4	
RoCE (%)	14.0	13.2	14.9		17.8	18.8	

Source: Company, ICICI Direct Research




Particulars

Particular	Amount
Market Cap (₹ Crore)	19,391
Total Debt (₹ Crore)	1,937
Cash (₹ Crore)	319
EV (₹ Crore)	21,010
52 week H/L	381/ 202
Equity capital	697.0
Face value	10.0

Shareholding pattern

	Sep-25	Dec-25	Mar-26	Jun-26
Promoter	54	54	54	54
FII	9	9	9	8
DII	25	25	25	25
Public	12	12	12	13

Price Chart



Key risks

- Delayed recovery for the exceptional items recorded this quarter;
- Slower than expected pipeline growth and deal conversion.

Research Analyst

Bhupendra Tiwary, CFA
bhupendra.tiwary@icicisecurities.com

CA Anjini Sharma
anjini.sharma@icicisecurities.com

Performance highlights and outlook

- **Revenue Performance:** FSL reported a revenue growth of 1.8% QoQ/11.2% YoY in US\$ terms (up 2.2% QoQ/12.3% YoY CC) to US\$ 288 mn. In rupee terms revenue grew 5.5% QoQ/22.9% YoY to ₹2,724.9 crore. Management highlighted this was also the ninth consecutive quarter of double-digit YoY revenue growth.
- **Geography performance:** Geography wise on a QoQ basis, US (66% of the mix) de-grew by 0.6% while UK/EMEA (32% of the mix) was up 5.4%, led by higher offshore and nearshore adoption.
 - Management expects Europe to continue improving supported by healthy deal conversions and South Africa-led delivery expansion, while also incubating new growth opportunities across Canada and Australia.
- **Segment performance:** Segment wise on a QoQ basis, growth was led by CMT (21% of the mix) and BFSI (33% of the mix) which grew by 5.3%, and 4.9% while Healthcare (32% of the mix) and Others – utilities and retail (13% of the mix) and declined by 2.4% and 0.5%.
 - **BFSI:** Grew 5% QoQ/14% YoY in CC terms with five new logo additions. Demand remained strong across intelligent operations, financial crime, compliance, collections and AI-enabled servicing, with one of the strongest deal pipelines in recent quarters.
 - **Healthcare:** Declined 2% QoQ but grew 11% YoY in CC terms due to program timing effects and wind-down of one BPaaS engagement following a client leadership change. **Management highlighted this as an isolated event, with the client relationship continuing to expand and healthcare remaining a key strategic growth vertical supported by strong AI-led RCM demand and healthy deal pipeline.**
 - **CMT:** Grew 9% QoQ/6% YoY in CC terms despite project timing volatility. Management expects growth to improve as program transitions conclude, supported by increasing AI-led opportunities across telecom, media and technology clients.
 - **Others (Utilities and Retail):** Grew 27% YoY and remained flat sequentially. Healthy pipeline, cross-selling opportunities through Pastdue Credit and seasonal normalization are expected to support improved momentum going ahead.
- **Margin performance:** EBIT margin expanded to 12.4%, up ~20 bps QoQ/~110 bps YoY, marking the seventh consecutive quarter of margin expansion. Reported PAT stood at ₹165.9 crore, down 19.2% QoQ/2% YoY, impacted by ₹71.7 crore of exceptional items relating to i) ₹35.7 crore provision for estimated non-recoverable dues following the termination of a healthcare BPaaS client contract owing to leadership change at the client side, (ii) ₹28.4 crore indemnification for a regulatory penalty payable to a customer (healthcare segment client) due to contractual non-fulfilment, and (iii) ₹7.6 crore fair value adjustment on contingent consideration related to an earlier acquisition. Both (i) and (ii) are largely recoverable and non-recurring in nature.
- **Outlook:** Management reaffirmed its FY27 guidance of 10–13% CC revenue growth and 12.25–12.75% EBIT margin, despite the wind-down of a healthcare BPaaS engagement that was expected to contribute 1–1.5% growth, citing add on work from the same client, its strongest deal pipeline in the last four quarters and faster ramp-up of recent large deals. **It also expects H2FY27 to be stronger as recent wins ramp over the next quarter. On the margins front, management reiterated its long-term margin expansion trajectory towards 14–15% EBIT margins over the next 2–3 years.**

- **Deal wins, new logos and Pipeline:** It won 4 large deals (ACV > \$5 million) and added 12 new logos, including 3 strategic logos (potential of at least a \$5 million revenue run-rate annually).
- **Attrition and employee addition:** The headcount increased by 670 QoQ to 36,875 employees. The attrition stood at 33.1%, up ~330 bps QoQ.

Exhibit 1: Quarter Performance

₹ crore	Q1FY27	Q1FY26	YoY (%)	Q4FY26	QoQ (%)	Comments
Revenue	2,724.9	2,217.7	22.9	2,583.5	5.5	- Revenue grew by 2.2% QoQ/12.3% YoY in CC terms - Management has maintained FY27 CC revenue growth guidance of 10-13% (~9.5% organic)
Employee expenses	1,531.6	1,320.7	17.6	1,476.6	4.1	
Gross Margin	1,193.3	897.0	33.0	1,106.8	7.8	
Gross margin (%)	43.8	40.4	335bps	42.8	95bps	
SG&A expenses	742.0	549.9	34.9	676.4	9.7	
EBITDA	451.3	347.1	30.0	430.4	4.9	
EBITDA Margin (%)	16.6	15.7	91bps	16.7	-10bps	
Depreciation & amortisation	114.6	97.2	17.9	116.1	-1.2	
EBIT	336.7	249.8	34.8	314.3	7.1	
EBIT Margin (%)	12.4	11.3	109bps	12.2	19bps	On the margins front, the management expects 50-75 bps expansion every year and has maintained a guidance of 12.25-12.75% EBIT margins for FY27
Other income (less interest)	-45.6	-36.6	24.7	-53.7	-15.0	
PBT	219.3	213.2	2.9	260.6	-15.8	
Tax paid	53.4	43.9	21.7	55.4	-3.5	
PAT	165.9	169.3	-2.0	205.2	-19.2	

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

(₹ Crore)	FY27E			FY28E		
	Old	New	% Change	Old	New	% Change
Revenue (USD mn)	1,195	1,193	-0.2	1,316	1,313	-0.2
Revenue	11,073	11,195	1.1	12,119	12,288	1.4
EBIT	1,373	1,387	1.0	1,527	1,548	1.4
EBIT Margin (%)	12.4	12.4	-1bps	12.6	12.6	0bps
PAT	973	908	-6.6	1,115	1,125	0.9
Diluted EPS (₹)	13.9	12.9	-6.6	15.9	16.0	0.9

Source: Company, ICICI Direct Research

Financial summary

Exhibit 3: Profit and loss statement		₹ crore		
(Year-end March)	FY26	FY27E	FY28E	
Total Revenues	9,556	11,195	12,288	
Growth (%)	19.7	17.1	9.8	
Employee expenses	5,590	6,487	7,189	
Other Expenses	2,410	2,826	2,998	
EBITDA	1,556	1,883	2,101	
Growth (%)	28.9	21.0	11.6	
Depreciation & Amortization	434	496	553	
Other Income	7	15	16	
Interest	181	172	140	
PBT before Exceptional Items	850	1,159	1,424	
Growth (%)	14.7	36.3	22.9	
Tax	175	251	299	
PAT before Excp Items	674	908	1,125	
Exceptional items				
PAT before MI	674	908	1,125	
Minority Int & Pft. from asso.	-	-	-	
PAT	674	908	1,125	
Growth (%)	13.5	34.6	23.9	
EPS	9.6	12.9	16.0	
EPS (Growth %)	13.5	34.6	23.9	

Source: Company, ICICI Direct Research

Exhibit 5: Balance sheet		₹ crore		
(Year-end March)	FY26	FY27E	FY28E	
Equity	697	697	697	
Reserves & Surplus	3,688	4,187	4,806	
Networth	4,385	4,884	5,503	
Minority Interest	0	0	0	
LT liabilities & provisions	1,267	1,267	1,267	
Total Debt	1,937	1,737	1,537	
Source of funds	7,589	7,889	8,308	
Net fixed assets	1,166	875	538	
CWIP	30	30	30	
Goodwill	4,266	4,266	4,266	
Other non current assets	1,096	1,180	1,235	
Loans and advances	-	-	-	
Current Investments	50	50	50	
Debtors	2,079	2,423	2,653	
Cash & Cash equivalents	269	658	1,279	
Other current assets	364	425	465	
Trade payables	558	650	712	
Current liabilities	1,040	1,213	1,328	
Provisions	132	154	169	
Application of funds	7,589	7,889	8,308	

Source: Company, ICICI Direct Research

Exhibit 4: Cash flow statement		₹ crore		
(Year-end March)	FY26	FY27E	FY28E	
Profit before Tax	850	1,159	1,424	
Dep & Amortization	434	496	553	
WC changes	(308)	(202)	(134)	
Other non cash adju.	238	(94)	(175)	
CF from operations	1,214	1,359	1,668	
Capital expenditure	(196)	(112)	(123)	
Δ in investments	(10)	-	-	
Other investing cash flow	4	15	16	
CF from Inv Activities	(452)	(97)	(107)	
Issue of equity	(50)	-	-	
Δ in debt funds	202	(200)	(200)	
Dividends paid	(380)	(409)	(506)	
Other financing cash flow	(179)	(172)	(140)	
CF from Fin Activities	(667)	(873)	(939)	
Δ in cash and cash bank	95	388	622	
Effect of exchange rate changes				
Opening cash	167	269	658	
Closing cash	269	658	1,279	

Source: Company, ICICI Direct Research

Exhibit 6: Key ratios		FY26		
(Year-end March)		FY26	FY27E	FY28E
Per share data (₹)				
EPS-diluted		9.6	12.9	16.0
DPS		4.3	5.8	7.2
BV		64.4	71.8	80.9
Operating Ratios (%)				
EBITDA Margin		16.3	16.8	17.1
PBT Margin		8.9	10.3	11.6
PAT Margin		7.1	8.1	9.2
Return Ratios (%)				
RoNW		15.4	18.6	20.4
RoCE		14.9	17.8	18.8
Valuation Ratios (x)				
P/E		28.8	21.4	17.2
EV / EBITDA		13.5	10.8	9.3
Price to Book Value		4.4	4.0	3.5
EV / Net Sales		2.2	1.8	1.6
Mcap / Net Sales		2.0	1.7	1.6
Turnover Ratios				
Debtor days		79	79	79
Creditors days		21	21	21
Solvency Ratios				
Total Debt / Equity		0.4	0.4	0.3
Current Ratio		1.4	1.4	1.4
Quick Ratio		1.4	1.4	1.4
Net Debt / EBITDA		1.0	0.5	0.1

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%

Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research
Desk,
ICICI Securities Limited,
Third Floor, Brillanto
House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Kaustubh Pawaskar, PGDBA (Finance), Abhishek Shankar, PGDM-RM, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Jeetu Jawrani Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report